Phase Ib/II study of the safety and efficacy of combination therapy with multikinase vascular endothelial growth factor inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma

Những quyển sách tương tự

• The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
  Bằng: Shroff, Rachna T, et al.
  Được phát hành: (2017)
• The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
  Bằng: Shroff, Rachna T, et al.
  Được phát hành: (2018)
• A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
  Bằng: Kurzrock, Razelle, et al.
  Được phát hành: (2019)
• Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors
  Bằng: Dembla, Vikas, et al.
  Được phát hành: (2017)
• Trametinib: a MEK inhibitor for management of metastatic melanoma
  Bằng: Lugowska, Iwona, et al.
  Được phát hành: (2015)